Ticagrelor – toward more efficient platelet inhibition and beyond
Michał J Kubisa,1 Mateusz P Jezewski,1 Aleksandra Gasecka,2,3 Jolanta M Siller-Matula,4 Marek Postuła1 1Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CEPT), 21st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland;...
Guardado en:
Autores principales: | Kubisa MJ, Jezewski MP, Gasecka A, Siller-Matula JM, Postuła M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5a84ed53a4944ffebd5335953cb8b901 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Response to antiplatelet therapy in patients undergoing invasive treatment due to acute coronary syndrome complicated by cardiogenic shock
por: Wiktor Kuliczkowski, et al.
Publicado: (2020) -
Ticagrelor vs. Clopidogrel After Complex Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease
por: Ziwei Xi, et al.
Publicado: (2021) -
Strategic approach to developing a self-microemulsifying drug delivery system to enhance antiplatelet activity and bioavailability of ticagrelor
por: Na YG, et al.
Publicado: (2019) -
Impact of Routine Platelet Reactivity Testing with VerifyNow Assay on Antiplatelet Choice After Percutaneous Coronary Intervention
por: Mshelbwala FS, et al.
Publicado: (2020) -
Antiplatelets in acute coronary syndrome in Poland – from guidelines to clinical practice
por: Stanisław Tubek, et al.
Publicado: (2021)